Andrew Hammer, MD
Ophthalmology · Washington, DCNPI 1720281181
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,250 of the $11,196 with a category attached, or 73.7%. Rxsight Inc accounts for 76.5% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $5,760, more than ten times the $331 reported in 2019. Among ophthalmology clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 107 payments — averaging $104.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$9K
- AbbVie$489
- Alcon$481
- NEW World Medical,inc.$424
- Mallinckrodt Hospital Products Inc.$248
- Mallinckrodt Enterprises LLC$116
- plus $871 from 18 others
Across 5 payments — averaging $6000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$30K
What the payments were for
- Consulting fees$8,25074%
- Food & beverage$2,84625%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 14 | $8,567 |
| AbbVie(2 entities) | 21 | $489 |
| Alcon | 14 | $481 |
| NEW World Medical,inc. | 2 | $424 |
| Mallinckrodt Hospital Products Inc. | 6 | $248 |
| Mallinckrodt Enterprises LLC | 5 | $116 |
| Dompe US, Inc. | 5 | $111 |
| Johnson & Johnson Vision Care, Inc. | 4 | $92 |
| Novartis | 6 | $88 |
| Oyster Point Pharma, Inc. | 4 | $78 |
| Amgen | 3 | $63 |
| Glaukos Corporation | 2 | $53 |
| Tarsus Pharmaceuticals, Inc. | 2 | $47 |
| Aerie Pharmaceuticals, Inc. | 3 | $45 |
| Harrow Eye, LLC | 2 | $43 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $37 |
| Ocular Therapeutix, Inc. | 2 | $35 |
| Kala Pharmaceuticals, Inc. | 2 | $35 |
| Sight Sciences, Inc. | 2 | $32 |
| Ivantis, Inc | 1 | $24 |
| Shire North American Group Inc | 1 | $19 |
| Alcon Research LLC | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,196 in reported general payments places this provider in the 90th percentile of 74 ophthalmology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 77 | $105,675 |
| LumiganBimatoprost | 29 | $20,822 |
| XiidraLifitegrast | 11 | $20,585 |
| Cyclosporine | 39 | $11,619 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $6,018 |
| Latanoprost | 366 | $5,119 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $3,881 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $3,395 |
| Travoprost | 15 | $3,198 |
| Timolol Maleate | 122 | $2,840 |
| Prednisolone Acetate | 53 | $2,164 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 41 | $1,810 |
| Brimonidine Tartrate | 55 | $1,806 |
| ValacyclovirValacyclovir Hcl | 18 | $1,117 |
| Ketorolac Tromethamine | 44 | $986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $489 | $132,515120 claims |
| AlconSimbrinza | $481 | $3,88114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 74 ophthalmology providers in District of Columbia.
Other ophthalmology in Washington
- Wiley ChambersWashington$618K
- Keesha Williams ElliottWashington$167K
- Samuel StopakWashington$33K
- Jonca BullWashington$30K
- Leslie JonesWashington$22K
- Alexander HacopianWashington$13K
- Mehdi Tavakoli DastjerdiWashington$12K
- Thandeka MyeniWashington$10K
- Dipak PanigrahiWashington$9K
- Jared EbertWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.